Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaHyperglycemia
Interventions
PROCEDURE

Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)

Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.

OTHER

Standard Care

Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.

Trial Locations (2)

V5Z 4E6

RECRUITING

British Columbia Cancer, Vancouver

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

University of British Columbia

OTHER

collaborator

Lustgarten Foundation

OTHER

collaborator

University Health Network, Toronto

OTHER

lead

British Columbia Cancer Agency

OTHER